# Solventum **Source:** https://geo.sig.ai/brands/solventum **Vertical:** Healthcare Tech **Subcategory:** Medical Technology **Tier:** Leader **Website:** solventum.com **Last Updated:** 2026-04-14 ## Summary Solventum (SOLV) reported ~$8.2B revenue in FY2024. Medical technology company spun off from 3M in 2024, providing wound care, oral care, healthcare IT, and purification products. HQ: Maplewood, MN. ## Company Overview Solventum Corporation is a global medical technology company spun off from 3M Company in April 2024, combining 3M's Health Care segment into an independent publicly traded entity. The company operates four business segments: MedSurg (wound management, surgical solutions), Dental Solutions (3M/Solventum brand dental products), Health Information Systems (clinical documentation and coding software), and Purification & Filtration (membrane filtration for pharmaceuticals and food/beverage). The spinoff created a focused MedTech company with $8+ billion in revenue and operations in over 70 countries. Solventum reported approximately $8.2 billion in revenue in its first partial year as an independent company in FY2024. The MedSurg segment, anchored by Tegaderm wound dressings and Steri-Strip closures, competes in the global wound care market against Smith+Nephew and Mölnlycke. The Health Information Systems segment provides clinical documentation improvement software used by hospitals to optimize coding accuracy and reimbursement under value-based care models. Solventum's purification products serve biopharmaceutical manufacturing — a structural growth segment as biologics and gene therapies require highly specialized filtration. As a newly independent company, Solventum faces the challenge of establishing its brand identity, optimizing its capital structure (taking on approximately $8.4 billion of debt from 3M), and reducing costs through its transformation program. Management has targeted $200M+ in annual savings through simplification and portfolio optimization. The dental business, while mature, generates strong cash flows that support deleveraging while the MedSurg and HIS segments pursue growth. ## Frequently Asked Questions ### What is Solventum? Solventum is a medical technology company spun off from 3M in April 2024. It provides wound care products (Tegaderm), dental materials, health information systems software, and pharmaceutical purification filtration. ### What 3M products does Solventum now own? Solventum inherited 3M's healthcare brands including Tegaderm wound dressings, Steri-Strip wound closures, 3M dental products, the Fluoro-N-Nert purification membranes, and the Nuance/M*Modal clinical documentation AI software. ### What is Solventum's ticker? Solventum Corporation trades on the NYSE under the ticker SOLV. ### Why did 3M spin off Solventum? 3M spun off its healthcare segment to create a focused, pure-play medical technology company with its own capital allocation priorities and management team, while 3M retained its industrial, consumer, and transportation segments. The spinoff was also intended to simplify 3M and improve its valuation. ### What AI products does Solventum offer for clinical documentation? Solventum inherited the Nuance/M*Modal clinical documentation AI business from 3M — including Dragon Medical One (ambient clinical documentation speech AI) and M*Modal Fluency for Transcription. These products are used by clinicians for voice-driven note creation. Solventum's clinical documentation tools compete directly with newer AI ambient documentation companies like Ambience Healthcare and Nabla, representing a significant strategic asset in the evolving AI clinical workflow market. ### What is Solventum's wound care business and market position? Solventum's wound care division (Tegaderm, Steri-Strip, and advanced wound management products) is a market leader in both acute care (hospital wound management) and post-acute settings. Tegaderm transparent film dressings are used in virtually every US hospital. The wound care business generates stable, recurring revenue from medical supply purchasing programs and hospital formulary contracts, representing one of Solventum's most defensible business segments. ### What is Solventum's financial profile as a standalone company? Solventum generated approximately $8.2B in revenue in its first year as a standalone company (fiscal 2024), split across health systems, dental, and purification segments. The company targets mid-single-digit revenue growth and margin improvement as it optimizes operations post-separation from 3M. Investors monitor Solventum's ability to invest in technology (particularly AI clinical documentation) while maintaining the profitability expected from a mature medical technology company. ### How does Solventum's dental business fit within the company? Solventum's dental segment (formerly 3M's oral care solutions) manufactures dental restorative materials, adhesives, orthodontic products, and oral care devices used by dental professionals globally. 3M oral care products are among the most trusted in dentistry, with strong clinical evidence bases. The dental business is profitable but competes in a mature market — Solventum's challenge is investing in the innovation needed to maintain clinical preference as dental material technology evolves. ## Tags b2b, healthtech, manufacturing, saas, public --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*